Abstract Silicone implants have been widely used for the fabrication of medical devices and implants due to their biocompatibility and inert properties. However, the contact with biological fluids and the ensuing surface adsorption of proteins often lead to the formation of biofilms such as capsular contracture (CC), requiring the removal of implants. Therefore, there has been an urgent demand for surface modification with biomaterials having anti-inflammatory, anti-microbial, and anti-fibrotic activities to prevent CC on silicone implants. Here, Itaconic acid (IA) conjugated with PDMS (IA-PDMS) and IA-conjugated gelatin polymer (IA-GTpoly) conjugated with PDMS (IA-GTpoly-PDMS) with various concentrations were examined as a candidate for inhibition of CC on the surface of PDMS. The IA-PDMS and IA-GTpoly-PDMS surfaces showed lower inflammation, in vivo capsule thickness, and collagen density than the bare PDMS did. Our results demonstrated the significant potential of IA based materials for surface modification of PDMS to develop biocompatible surfaces for various biomedical devices.

中文翻译：

---

衣康酸共轭明胶表面改性抑制聚（二甲基硅氧烷）医用植入物的包膜挛缩

摘要 有机硅植入物由于其生物相容性和惰性特性而被广泛用于制造医疗器械和植入物。然而，与生物体液的接触以及随之而来的蛋白质的表面吸附通常会导致生物膜的形成，例如包膜挛缩 (CC)，需要移除植入物。因此，迫切需要用具有抗炎、抗微生物和抗纤维化活性的生物材料进行表面改性，以防止硅胶植入物上的 CC。在这里，衣康酸 (IA) 与不同浓度的 PDMS (IA-PDMS) 和 IA 共轭明胶聚合物 (IA-GTpoly) 与不同浓度的 PDMS (IA-GTpoly-PDMS) 结合作为抑制 CC 的候选物。 PDMS 的表面。IA-PDMS 和 IA-GTpoly-PDMS 表面显示出较低的炎症，体内胶囊厚度和胶原密度比裸 PDMS 好。我们的结果证明了基于 IA 的材料在 PDMS 表面改性方面的巨大潜力，可以为各种生物医学设备开发生物相容性表面。